Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350636 · ClinicalTrials.gov registry record · Phase 3
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
A Phase 3 study, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 789
- Enrollment target
NCT00350636 is a Phase 3 study that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 789 participants.
The verdict
NCT00350636, a Phase 3 study, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 789 participants
- Enrollment target
Study Summary
A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
Interventions
- DRUG Oxybutynin topical gel
- OTHER Placebo topical gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 789 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00350636
The ClinicalTrials.gov registry entry for NCT00350636 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 789 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxybutynin topical gel is the first listed.
NCT00350636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00350636 about?
NCT00350636 is a clinical study titled "A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo". A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
What is the current status of trial NCT00350636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 789 participants. The study started on 2006-06. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00350636?
The interventions under investigation include: Oxybutynin topical gel (DRUG), Placebo topical gel (OTHER).
Who is sponsoring clinical trial NCT00350636?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.